Bone Mineral at Sites of Increased Osteogenesis (Metastatic Bone Lesions)

Bone mineral at sites of increased osteogenesis within metastatic lesions represents newly deposited yet structurally inferior hydroxyapatite/collagen composite laid down under dysregulated conditions induced primarily by cancer-bone interactions. It is an important target for imaging diagnostics—and potentially therapy—in patients with advanced malignancies affecting the skeleton. The newly formed mineral at these sites tends to have a lower degree of mineralization, altered crystal structure, and reduced enzymatic collagen crosslinks, leading to mechanically weaker bone despite increased density on imaging.

Other names

Osteoblastic MetastasesMetastatic Bone Lesions (Osteoblastic)Sites of Increased Bone Formation in Metastatic Disease

Bisphosphonates: Inhibit osteoclast-mediated bone resorption. Denosumab: RANKL inhibitor, preventing osteoclast formation and activity.